Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood

Dania Vázquez-Blomquist , Mónica Bequet-Romero , Yssel Mendoza-Marí , Gilda Lemos , Iris Valdés , Camila Canaán-Haden Ayala , Isabel Gonzáles Moya , Ricardo Martínez Rosales , Giselle Freyre Corrales , Gerardo Guillén-Nieto
{"title":"Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood","authors":"Dania Vázquez-Blomquist ,&nbsp;Mónica Bequet-Romero ,&nbsp;Yssel Mendoza-Marí ,&nbsp;Gilda Lemos ,&nbsp;Iris Valdés ,&nbsp;Camila Canaán-Haden Ayala ,&nbsp;Isabel Gonzáles Moya ,&nbsp;Ricardo Martínez Rosales ,&nbsp;Giselle Freyre Corrales ,&nbsp;Gerardo Guillén-Nieto","doi":"10.1016/j.clicom.2022.02.002","DOIUrl":null,"url":null,"abstract":"<div><p>We conducted an experimental protocol with a nasal recombinant IFNα-2b formulation (Nasalferon) in 12 healthy volunteers who received 1 MIU per nostril twice a day, three consecutive days, and studied the induction of biomarkers related to antiviral and immune responses. Nasalferon increases the antiviral biomarker OAS1 transcript levels in oropharynx and PBMCs, regulates molecular and cellular elements related to innate and adaptive immune responses and decreases granulocytes population. These effects support Nasalferon use in virally-exposed populations.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772613422000051/pdfft?md5=92213432cd7e3694dd11ab0804a3bb79&pid=1-s2.0-S2772613422000051-main.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772613422000051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

We conducted an experimental protocol with a nasal recombinant IFNα-2b formulation (Nasalferon) in 12 healthy volunteers who received 1 MIU per nostril twice a day, three consecutive days, and studied the induction of biomarkers related to antiviral and immune responses. Nasalferon increases the antiviral biomarker OAS1 transcript levels in oropharynx and PBMCs, regulates molecular and cellular elements related to innate and adaptive immune responses and decreases granulocytes population. These effects support Nasalferon use in virally-exposed populations.

Nasalferon是一种新的IFNα2b鼻用制剂,可调节粘膜和血液中与抗病毒反应相关的细胞和分子因子
我们对12名健康志愿者进行了鼻用重组IFNα-2b制剂(Nasalferon)的实验方案,这些志愿者每天两次每次鼻孔1 MIU,连续3天,研究了与抗病毒和免疫反应相关的生物标志物的诱导。纳沙非龙增加口咽部和PBMCs中抗病毒生物标志物OAS1转录物水平,调节与先天和适应性免疫反应相关的分子和细胞元件,减少粒细胞数量。这些影响支持在病毒暴露人群中使用纳沙非龙。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信